Right Heart Failure in Chronic Lung Disease. Where Are We Now?

1992 ◽  
pp. 1-9 ◽  
Author(s):  
V. Ježek ◽  
M. Morpurgo
Keyword(s):  
Heart Failure ◽  
Lung Disease ◽  
Chronic Lung Disease ◽  
Right Heart Failure ◽  
Right Heart

scholarly journals Pulmonary Hypertension and Right Heart Dysfunction in Chronic Lung Disease

2014 ◽  
Vol 2014 ◽  
pp. 1-13 ◽  
Author(s):  
Amirmasoud Zangiabadi ◽  
Carmine G. De Pasquale ◽  
Dimitar Sajkov
Keyword(s):  
Pulmonary Hypertension ◽  
Lung Disease ◽  
Chronic Lung Disease ◽  
Hypoxic Pulmonary Vasoconstriction ◽  
Right Heart Failure ◽  
Chronic Obstructive ◽  
Heart Catheterization ◽  
Right Heart ◽  
Phosphodiesterase Type 5 Inhibitors ◽  
Number Of Patients

Group 3 pulmonary hypertension (PH) is a common complication of chronic lung disease (CLD), including chronic obstructive pulmonary disease (COPD), interstitial lung disease, and sleep-disordered breathing. Development of PH is associated with poor prognosis and may progress to right heart failure, however, in the majority of the patients with CLD, PH is mild to moderate and only a small number of patients develop severe PH. The pathophysiology of PH in CLD is multifactorial and includes hypoxic pulmonary vasoconstriction, pulmonary vascular remodeling, small vessel destruction, and fibrosis. The effects of PH on the right ventricle (RV) range between early RV remodeling, hypertrophy, dilatation, and eventual failure with associated increased mortality. The golden standard for diagnosis of PH is right heart catheterization, however, evidence of PH can be appreciated on clinical examination, serology, radiological imaging, and Doppler echocardiography. Treatment of PH in CLD focuses on management of the underlying lung disorder and hypoxia. There is, however, limited evidence to suggest that PH-specific vasodilators such as phosphodiesterase-type 5 inhibitors, endothelin receptor antagonists, and prostanoids may have a role in the treatment of patients with CLD and moderate-to-severe PH.

scholarly journals Pulmonary vascular and cardiac impairment in interstitial lung disease

2017 ◽  
Vol 26 (143) ◽  
pp. 160053 ◽  
Author(s):  
Marios Panagiotou ◽  
Alistair C. Church ◽  
Martin K. Johnson ◽  
Andrew J. Peacock
Keyword(s):  
Heart Failure ◽  
Pulmonary Hypertension ◽  
Interstitial Lung Disease ◽  
Natural History ◽  
Lung Disease ◽  
Pulmonary Vascular Resistance ◽  
Right Heart Failure ◽  
Right Heart ◽  
History Of ◽  
Adverse Factor

Pulmonary vascular and cardiac impairment is increasingly appreciated as a major adverse factor in the natural history of interstitial lung disease. This clinically orientated review focuses on the current concepts in the pathogenesis, pathophysiology and implications of the detrimental sequence of increased pulmonary vascular resistance, pre-capillary pulmonary hypertension and right heart failure in interstitial lung disease, and provides guidance on its management.

Different cell death mechanisms are triggered by acute or chronic right heart failure-induced liver failure

2011 ◽  
Vol 49 (01) ◽  
Author(s):  
K Herzer ◽  
G Kneiseler ◽  
F Post ◽  
M Schlattjan ◽  
T Neumann ◽  
...  
Keyword(s):  
Heart Failure ◽  
Cell Death ◽  
Liver Failure ◽  
Right Heart Failure ◽  
Right Heart ◽  
Cell Death Mechanisms

0170 Subclinical right heart failure may contribute to the development of liver disease in feedlot cattle during the finishing phase.

2016 ◽  
Vol 94 (supplement5) ◽  
pp. 82
Author(s):  
A. K. Gulick ◽  
K. M. Freeman ◽  
B. C. Bernhard ◽  
J. O. Sarturi ◽  
J. M. Neary
Keyword(s):  
Heart Failure ◽  
Liver Disease ◽  
Right Heart Failure ◽  
Feedlot Cattle ◽  
Right Heart
Sign in / Sign up

Export Citation Format

Share Document